Related Experiment Videos
Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines
K McLaughlin1, G Coren, J Masters
1CRC Department of Medical Oncology, Beatson Laboratories, Glasgow, UK.
Abstract:
Proteins can be detected by South-western analyses of human tumour-cell extracts binding to double-stranded oligonucleotide DNA treated in vitro with the chemotherapeutic drug cis-diamminedichloroplatinum (II) (CDDP), but not to untreated DNA. The relative molecular masses of proteins binding to the CDDP-treated double-stranded oligonucleotide are 25, 48 and 97 kDa. The binding activity of 2 of the CDDP-damage-recognition proteins, of relative molecular mass 48 and 97 kDa, is greater in a CDDP-resistant human ovarian tumour cell line than in the parental sensitive line. South-western analysis of a panel of human bladder cell lines and CDDP-sensitive testicular cell lines show consistent patterns of CDDP-damage-recognition proteins within each cell type, however with differences between the 2 cell types. Binding of the proteins to CDDP-damaged DNA and the altered binding activity detected in tumour cell lines suggests that alteration in damage-recognition proteins could play a role in tumour response to CDDP.
Insights
Researchers identified specific proteins that recognize DNA damage caused by the chemotherapy drug cisplatin (CDDP). Altered levels of these CDDP-damage-recognition proteins in tumor cells may influence treatment effectiveness.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Resistance
Background:
- Cis-diamminedichloroplatinum (II) (CDDP) is a platinum-based chemotherapy drug.
- Tumor cells can develop resistance to CDDP, limiting treatment efficacy.
- Understanding DNA damage recognition mechanisms is crucial for cancer therapy.
Purpose of the Study:
- To identify proteins that bind to CDDP-damaged DNA in human tumor cells.
- To investigate the role of these DNA damage-recognition proteins in CDDP sensitivity and resistance.
Main Methods:
- South-western analysis of human tumor cell extracts.
- In vitro binding assays with CDDP-treated and untreated double-stranded oligonucleotide DNA.
- Comparison of protein binding patterns across sensitive and resistant cell lines.
Main Results:
- Proteins with relative molecular masses of 25, 48, and 97 kDa were found to bind CDDP-treated DNA.
- Higher binding activity of 48 and 97 kDa proteins was observed in CDDP-resistant ovarian tumor cells.
- Distinct patterns of CDDP-damage-recognition proteins were found in bladder and testicular cell lines.
Conclusions:
- Alterations in CDDP-damage-recognition proteins may be associated with tumor response to CDDP.
- These proteins represent potential biomarkers for predicting treatment outcomes.
- Further research into these proteins could lead to novel therapeutic strategies.